Article
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
Haematologica - 1 Jun 2025
Senapati Jayastu, Loghavi Sanam, Garcia-Manero Guillermo, Tang Guillin, Kadia Tapan, Short Nicholas J, Abbas Hussein A, Arani Naszrin, DiNardo Courtney D, Borthakur Gautam, Pemmaraju Naveen, Oran Betul, Shpall Elizabeth, Popat Uday, Champlin Richard, Pierce Sherry, Arora Sankalp, Issa Ghayas, Yilmaz Musa, Patel Keyur, Takahashi Koichi, Montalban-Bravo Guillermo, Hammond Danielle, Haddad Fadi G, Ravandi Farhad, Kantarjian Hagop M, Daver Naval G
Abstract excerpt
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic decisions and prognostication. This retrospective analysis included patients with newly diagnosed MDS (>5% blasts) and AML with TP53 mutation(s) treated at MD Anderson Cancer Center. We factored patient age, TP53...
Topics
- Humans
- Aged
- Tumor Suppressor Protein p53
- Male
- Female
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
- Middle Aged